Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group study 9916

Authors
Hussain, M Petrylak, D Fisher, E Tangen, C Crawford, D
Citation
M. Hussain et al., Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group study 9916, SEMIN ONCOL, 26(5), 1999, pp. 55-60
Citations number
25
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
SEMINARS IN ONCOLOGY
ISSN journal
00937754 → ACNP
Volume
26
Issue
5
Year of publication
1999
Supplement
17
Pages
55 - 60
Database
ISI
SICI code
0093-7754(199910)26:5<55:D(AEVM>2.0.ZU;2-J